Detalhe da pesquisa
1.
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.
Cancer
; 129(11): 1704-1713, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36932983
2.
Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With Ruxolitinib.
JCO Precis Oncol
; 8: e2300593, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38484210
3.
Sustained response off therapy after fostamatinib: A chronic refractory ITP case report.
Heliyon
; 9(2): e13462, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36846652
4.
Immune Thrombocytopenia Onset and Relapse During the COVID-19 Pandemic. A Monocenter Study.
Mediterr J Hematol Infect Dis
; 15(1): e2023029, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37180204
5.
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study.
Cancers (Basel)
; 15(14)2023 Jul 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37509367
6.
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib.
Blood Cancer J
; 13(1): 65, 2023 05 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37137878
7.
Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity.
Leuk Res
; 116: 106819, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35303626